Please assess the completion status of the following clinical trial:

Trial Title: Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity.~* Subject is willing to adhere to the visit/protocol schedules.~* Subject meets the diagnosis of gout as per the American Rheumatism Association~* Criteria for the Classification of Acute Arthritis of Primary Gout.~* Subject meets one of the following criteria:~* Subjects who are not currently taking an approved ULT must have an sUA value of ≥ 8 mg/dL (476 µmol/L).~* Subjects entering the study on a medically appropriate dose of febuxostat or allopurinol must have an sUA value of ≥ 6.0 mg/dL (357 µmol/L).~* Subject must be able to take gout flare prophylaxis with colchicine or non-steroidal anti-inflammatory drug (NSAID) (including Cox-2 selective NSAID) ± PPI.~* Subject with at least 1 measurable tophus on the hands/wrists and/or feet/ankles ≥ 5 mm and ≤ 20 mm in the longest diameter.~* Body mass index (BMI) \< 45 kg/m2~Exclusion Criteria:~* Subject with known hypersensitivity or allergy to febuxostat.~* Subject who is taking any approved urate-lowering medication other than allopurinol or febuxostat that is indicated for the treatment of gout within 8 weeks of the Screening Visit.~* Subject who previously received pegloticase.~* Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz \[150 mL\] of wine, 12 oz \[360 mL\] of beer, or 1.5 oz \[45 mL\] of hard liquor).~* Subject with a history or suspicion of drug abuse within the past 5 years.~* Subject with a history of myositis/myopathy or rhabdomyolysis.~* Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment.~* Subject with known or suspected human immunodeficiency virus (HIV) infection.~* Subject with a positive test for active hepatitis B or hepatitis C infection.~* Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer.~* Subject within the last 12 months with: unstable angina, New York Heart Association thrombosis; or subjects currently receiving anticoagulants.~* Subject with uncontrolled hypertension.~* Subject with an estimated creatinine clearance \< 30 mL/min.~* Subjects with a creatine kinase \> 2.5 x ULN at any time during the Screening Period.~* Subject with active peptic ulcer disease requiring treatment.~* Subject with a history of xanthinuria, active liver disease, or hepatic dysfunction.~* Subject receiving chronic treatment with more than 325 mg of salicylates per day.~* Subject taking valpromide, progabide, or valproic acid.~* Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit.~* Subject with any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- lesinurad 400 mg + febuxostat 80 mg (Type: EXPERIMENTAL): None
- lesinurad 200 mg + febuxostat 80 mg (Type: EXPERIMENTAL): None
- placebo + febuxostat 80 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete